128 related articles for article (PubMed ID: 26933863)
1. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.
Tsuda K; Tanimoto T; Komatsu T
N Engl J Med; 2016 Feb; 374(8):792-3. PubMed ID: 26933863
[No Abstract] [Full Text] [Related]
2. Lenalidomide plus Rituximab for Mantle-Cell Lymphoma.
Ruan J; Leonard JP
N Engl J Med; 2016 Feb; 374(8):793. PubMed ID: 26933862
[No Abstract] [Full Text] [Related]
3. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
[TBL] [Abstract][Full Text] [Related]
4. Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi- center phase II study of lenalidomide plus rituximab.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):17-8. PubMed ID: 24870878
[No Abstract] [Full Text] [Related]
5. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
7. Autologous transplantation and management of younger patients with mantle cell lymphoma.
Geisler CH
Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457
[TBL] [Abstract][Full Text] [Related]
8. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial.
Laurell A; Kolstad A; Jerkeman M; Räty R; Geisler CH
Leuk Lymphoma; 2014 May; 55(5):1206-8. PubMed ID: 23876100
[No Abstract] [Full Text] [Related]
9. Treatment of older patients with mantle-cell lymphoma.
Takahashi Y; Mori J; Tanimoto T
N Engl J Med; 2012 Nov; 367(18):1765; author reply 1765-6. PubMed ID: 23113500
[No Abstract] [Full Text] [Related]
10. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
[TBL] [Abstract][Full Text] [Related]
11. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.
Zaja F; Ferrero S; Stelitano C; Ferrari A; Salvi F; Arcari A; Musuraca G; Botto B; Spina M; Cellini C; Patti C; Liberati AM; Minotto C; Pileri SA; Ceccarelli M; Volpetti S; Ferranti A; Drandi D; Montechiarello E; Ladetto M; Carmichael J; Fanin R
Haematologica; 2017 May; 102(5):e203-e206. PubMed ID: 28082342
[No Abstract] [Full Text] [Related]
12. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
13. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Ruan J; Martin P; Coleman M; Furman RR; Cheung K; Faye A; Elstrom R; Lachs M; Hajjar KA; Leonard JP
Cancer; 2010 Jun; 116(11):2655-64. PubMed ID: 20235190
[TBL] [Abstract][Full Text] [Related]
14. New combinations for mantle cell lymphoma: concerted action needed.
Hess G
Lancet Oncol; 2011 Apr; 12(4):315-6. PubMed ID: 21440504
[No Abstract] [Full Text] [Related]
15. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
16. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.
Chong EA; Ahmadi T; Aqui NA; Svoboda J; Nasta SD; Mato AR; Walsh KM; Schuster SJ
Clin Cancer Res; 2015 Apr; 21(8):1835-42. PubMed ID: 25632047
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
Cheah CY; Nastoupil LJ; Neelapu SS; Forbes SG; Oki Y; Fowler NH
Blood; 2015 May; 125(21):3357-9. PubMed ID: 25999447
[No Abstract] [Full Text] [Related]
20. [Progressive multifocal leukoencephalopathy after rituximab therapy in a patient with mantle cell lymphoma].
Ota I; Katsura Y; Yoshida C; Yoshizawa K; Ohtani H; Sata T; Komeno T
Rinsho Ketsueki; 2010 Dec; 51(12):1786-8. PubMed ID: 21258190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
